<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01629394</url>
  </required_header>
  <id_info>
    <org_study_id>952/21-3-12</org_study_id>
    <nct_id>NCT01629394</nct_id>
  </id_info>
  <brief_title>Comparative Study of Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade in Morbidly Obese Patients</brief_title>
  <official_title>Comparative Study of Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade in Morbidly Obese Patients Undergoing Weight Loss Surgery.Use of Acceleromyography Monitoring in Adductor Pollicis and Corrugator Supercilii.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative residual curarization in the post anaesthesia unit has been associated to
      complications involving respiratory function and impaired laryngeal and pharyngeal muscles'
      function. Speed of reversal of neuromuscular blockade after administration of sugammadex
      versus neostigmine has been studied, but up to date no data are available concerning
      continuous acceleromyography monitoring of adductor pollicis and corrugator supercilii in
      morbidly obese patients undergoing weight loss surgery. The investigators' aim in this
      prospective, double-blinded study was to compare train of four ( TOF ) values, the presence
      or absence of clinical criteria of postoperative residual curarization , the dose
      requirements and the side effects of sugammadex and neostigmine for the reversal of
      rocuronium induced neuromuscular blockade in patients undergoing laparoscopic or open surgery
      for morbid obesity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Morbidly obese patients [ body mass index (BMI) &gt; 40 kg/m2 ] planned to undergo open or
      laparoscopic surgery for weight loss will be managed with standardized general anesthesia
      (intravenous Propofol combined with remifentanil and muscle relaxation induced by
      rocuronium).

      By the end of the surgery, Group A and group E patients will receive sugammadex 2 mg/kg
      corrected body weight [corrected body weight(CBW)=ideal body weight(IBW) + 40%(real body
      weight(RBW)-ideal body weight)] when T2 arises in adductor pollicis. Group C and group G will
      receive neostigmine 50μg/kg corrected body weight when T2 arises in adductor pollicis. Group
      B and group F patients will receive sugammadex 2 mg/kg ideal body weight when T2 arises in
      adductor pollicis. Group D and group H patients will receive 50μg/kg neostigmine ideal body
      weight.

      Investigators will proceed in continuous acceleromyography monitoring of adductor pollicis
      and corrugator supercilii during induction of anaesthesia, surgery, recovery and in the post
      anaesthesia care unit, recording TOF values. Total consumption of neuromuscular blocking
      agent, doses of reversal agents and clinical criteria of post operation residual curarization
      will also be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Speed of reversal of neuromuscular blockade after administration of different sugammadex/neostigmine doses to TOF values = 0.9 in adductor pollicis and corrugator supercilii</measure>
    <time_frame>TOF values for 2.5 h postoperatively</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Morbid Obesity</condition>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Group A: Sugammadex CBW-open</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A patients will undergo open surgery and will receive sugammadex 2mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)] when T2 arises in adductor pollicis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Sugammadex IBW-open</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B patients will undergo open surgery and will receive sugammadex 2mg/kg ( ideal body weight ) when T2 arises in adductor pollicis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: Neostigmine CBW-open</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group C patients will undergo open surgery and will receive neostigmine 50μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]when T2 arises in adductor pollicis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: Neostigmine-IBW</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group D patients will undergo open surgery and will receive neostigmine 50μg/kg ( ideal body weight ) when T2 arises in adductor pollicis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E: Sugammadex CBW-Lap</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group E patients will undergo laparoscopic surgery and will receive sugammadex 2mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)] when T2 arises in adductor pollicis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F: Sugammadex IBW-Lap</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group F patients will undergo laparoscopic surgery and will receive sugammadex 2mg/kg ( ideal body weight ) when T2 arises in adductor pollicis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G: Neostigmine CBW-Lap</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group C patients will undergo laparoscopic surgery and will receive neostigmine 50μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]when T2 arises in adductor pollicis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H: Neostigmine IBW-Lap</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group D patients will undergo open surgery and will receive neostigmine 50μg/kg ( ideal body weight ) when T2 arises in adductor pollicis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Single dose of 2 mg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]</description>
    <arm_group_label>Group A: Sugammadex CBW-open</arm_group_label>
    <other_name>Bridion(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Single dose of sugammadex 2 mg/kg ( ideal body weight )</description>
    <arm_group_label>Group B: Sugammadex IBW-open</arm_group_label>
    <other_name>Bridion(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Single dose of neostigmine 50 μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]</description>
    <arm_group_label>Group C: Neostigmine CBW-open</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Single dose of neostigmine 50 μg/kg ( ideal body weight )</description>
    <arm_group_label>Group D: Neostigmine-IBW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Single dose of 2 mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)]</description>
    <arm_group_label>Group E: Sugammadex CBW-Lap</arm_group_label>
    <other_name>Bridion(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Single dose of sugammadex 2 mg/kg ( ideal body weight )</description>
    <arm_group_label>Group F: Sugammadex IBW-Lap</arm_group_label>
    <other_name>Bridion(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Single dose of neostigmine 50 μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]</description>
    <arm_group_label>Group G: Neostigmine CBW-Lap</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Single dose of neostigmine 50μg/kg ( ideal body weight )</description>
    <arm_group_label>Group H: Neostigmine IBW-Lap</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) &gt;40kg

          -  Age &lt; 60

          -  Patients written consent to participate in the study

        Exclusion Criteria:

          -  Cardiovascular disease (NYHA&gt;2)

          -  Patients refusal to participate in the study

          -  Contraindication to epidural catheter placement (e.g anticoagulation, anti- platelets
             medication)

          -  coexisting neuromuscular disease

          -  history of allergic reaction to neuromuscular blocking agents

          -  history of difficult intubation

          -  creatinine levels &gt; 159lmol/l
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prokopios S. Georgiou, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Patras</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kriton S. Filos, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Patras, Dept. of Anaesthesiology and Critical Care Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Athena Siampalioti, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Patras</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prokopios Georgiou, MD</last_name>
    <phone>00306973440348</phone>
    <email>prgeorg@yahoo.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kriton S. Filos, MD PhD</last_name>
    <phone>00302610999341</phone>
    <email>kritonfilos@yahoo.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Patras, Department of Anesthesiology and Critical Care Medicine</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kriton S. Filos, MD PhD</last_name>
      <phone>00302610999341</phone>
      <email>kritonfilos@yahoo.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2012</study_first_submitted>
  <study_first_submitted_qc>June 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2012</study_first_posted>
  <last_update_submitted>June 25, 2012</last_update_submitted>
  <last_update_submitted_qc>June 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>Prokopios Georgiou</investigator_full_name>
    <investigator_title>Prokopios Georgiou M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

